Cannabinoid News and Research

Latest Cannabinoid News and Research

Cannabis and the endocannabinoid system: an interview with Dr Leonora Long

Cannabis has both physical and behavioural effects. People using cannabis can experience feelings of euphoria (well-being), hunger, sleepiness, problems with motor coordination, and sometimes feelings of anxiety and paranoia.

15 Oct 2012

Increasing marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X

American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

MDA7 compound shows promise against Alzheimer's disease

A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

3 Sep 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

New drug can aid in losing weight and keeping it off

A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

28 Jul 2012

Researchers identify cannabinoid-making pathway

U of S researchers have discovered the chemical pathway that Cannabis sativa uses to create bioactive compounds called cannabinoids, paving the way for the development of marijuana varieties to produce pharmaceuticals or cannabinoid-free industrial hemp.

17 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.

19 Jun 2012

Study finds no evidence to support an effect of THC on MS progression

The first large non-commercial study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS) shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

16 Jun 2012

Study determines transgenerational effects of cannabinoid exposure in adolescent female rats

Mothers who use marijuana as teens-long before having children-may put their future children at a higher risk of drug abuse, new research suggests.

6 Jun 2012

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain

An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.

5 Jun 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Cannabinoid drugs can directly inhibit HIV in late-stage AIDS

Mount Sinai School of Medicine researchers have discovered that marijuana-like chemicals trigger receptors on human immune cells that can directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS, according to new findings published online in the journal PLoS ONE.

21 Mar 2012

CB2 receptor involved in regulating impulsive behaviour

A new study lead by the Neuroscience Institute of Alicante reveals how manipulating the endocannabinoid system can modulate high levels of impulsivity. This is the main problem in psychiatric illnesses such a schizophrenia, bipolar disorder and substance abuse.

8 Mar 2012

Researchers identify mechanism by which cannabis affects working memory

A deterioration of working memory is observed in people who consume drugs containing cannabinoid compounds found in cannabis leaves and buds. A team led by Giovanni Marsicano in collaboration with a team led by Xia Zhang, has recently identified the mechanism by which these substances affect working memory.

3 Mar 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012